Outcome Predictors of Candida Prosthetic Joint Infections: A Systematic Review and Meta-analysis
-
By
-
Charles Gibert
-
Camille Marchetti
-
Benoît Guery
-
Sylvain Steinmetz
-
Tristan Ferry
-
Frederic Lamoth
-
May 14, 2025
-
Clinical Scorecard: Predictors of Outcomes in Candida-Related Prosthetic Joint Infections: A Comprehensive Review and Meta-Analysis
At a Glance
| Category | Detail |
|---|
| Condition | Candida prosthetic joint infections (CPJI) |
| Key Mechanisms | Biofilm formation by Candida spp. complicates treatment; polymicrobial infections common; limited antifungal options |
| Target Population | Adult patients (≥18 years) with Candida infection of hip or knee prosthetic joints |
| Care Setting | Orthopedic surgical and infectious disease management settings, including hospitals performing arthroplasty and revision surgeries |
Key Highlights
- Complete prosthesis removal is strongly recommended for successful CPJI management.
- Co-infection with Staphylococcus aureus and retention of prosthesis after debridement predict treatment failure.
- First-line therapy with amphotericin B is associated with higher treatment success compared to other antifungals.
Guideline-Based Recommendations
Diagnosis
- Microbiological identification of Candida species from prosthetic material, periprosthetic tissue, or joint fluid via culture or molecular methods.
- Consider polymicrobial infections, especially with Staphylococcus aureus.
Management
- Complete hardware removal is essential; debridement with retention of prosthesis is linked to higher failure rates.
- No significant difference in outcomes among 1-stage, 2-stage, or 3-stage prosthesis exchange procedures.
- Use amphotericin B as first-line systemic antifungal therapy.
- Local antifungal therapy (e.g., drug-impregnated spacers) has no demonstrated impact on outcomes.
Monitoring & Follow-up
- Monitor for signs of treatment failure, especially in cases with Staphylococcus aureus co-infection or retained prosthesis.
- Assess response to amphotericin B therapy and adjust management accordingly.
Risks
- Higher risk of failure with prosthesis retention and Staphylococcus aureus co-infection.
- Limited efficacy of local antifungal therapies and triazoles or echinocandins as first-line agents.
Patient & Prescribing Data
Adults with Candida prosthetic joint infections, including hip and knee arthroplasties
Amphotericin B as initial antifungal therapy significantly improves treatment success; polymicrobial infections require careful management.
Clinical Best Practices
- Prioritize complete removal of infected prosthetic hardware in CPJI cases.
- Initiate systemic antifungal therapy with amphotericin B promptly after diagnosis.
- Avoid prosthesis retention strategies unless absolutely necessary due to higher failure risk.
- Recognize and manage co-infections, particularly with Staphylococcus aureus, to improve outcomes.
- Do not rely on local antifungal therapies alone as they have no proven benefit.
References
